Tagged with Switzerland

Switzerland Stefan Frefel, CEO of Bilfinger Industrial Services in Switzerland, outlines Bilfinger’s core offering of maintenance and engineering services to the pharmaceutical industry, the importance of the Swiss affiliate to the global group, and how the company is positioning itself at the forefront of digital disruption and other new industry trends.…

Switzerland Jonathan Koch, group president R&D Laboratories at Swiss-based CRO, Covance, explains how the integration process with LabCorb has progressed over the last two years, Covance’s embrace of digitally disruptive technologies, and becoming a “flexible service provider.” Two years on from LabCorp’s headline-making acquisition of Covance, how has the integration process…

Switzerland Marc Funk, COO of Swiss-headquartered product development service specialist, Lonza, discusses the company’s remarkable recent fortunes, how it is implementing innovative efficiency improvements, and answers the question, “why Switzerland?”   We aspire to move the company and the relationship with our customers from being a functional service provider to the strategic partner…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…

Switzerland Oliver Rinner, CEO and founder of Biognosys, provides a fascinating account of the company’s unique business model and explains how its technical research into proteomics and cell expression is likely to be even more successful despite continuous technological developments. Biognosys – a proteomics focused company – was initially founded as…

Switzerland Marina Lugova, executive VP Business Development at API manufacturer Synbias Pharma, discusses why Switzerland was chosen as the company’s headquarters, Synbias’s internationalization strategy, and why it is the partner of choice.   We have chosen Switzerland for several reasons: a stable political and economic environment, the fact many Big Pharma…

Switzerland Petra Exner and Tobias Haber discuss the unique service offering of INSIGHT Health, one of the leading data providers to the healthcare market, the company’s successful internationalization strategy, and why INSIGHT Health is the partner of choice. Could you begin by introducing INSIGHT Health to our international audience? “We should…

Switzerland Rocco Donnino, executive vice president of corporate development of AppRiver AG, a cybersecurity company with headquarters in Switzerland and Florida, US, discusses the strategic steps in establishing AppRiver across Europe and the services they provide, specifically the layered security approach portrayed throughout the healthcare and life science sector. Furthermore, he…

Switzerland Thomas Huber, CEO of Skan Group in Switzerland, a global leader in clean room equipment for the life sciences industry, discusses adapting to an ever-changing regulatory environment, Skan’s unique solutions, and its steadily-increasing international footprint. You joined Skan AG 21 years ago, gradually making it up to the top position…

Switzerland In an exclusive interview, Jean-Paul Clozel, former head of Actelion and now CEO of exciting biotech newcomer Idorsia, discusses his new company’s unique drug discovery methodology, the pressure of past success, and how he hopes to usher in a new era of collaboration to tackle disease.   In August 2016,…

Switzerland Thierry Mauvernay, president and delegate of the board of Debiopharm, discusses the Swiss Group’s development over its 38 years of history, its unique business strategy, and how new trends such as personalized medicine and digitalization are being embraced moving forward.   Our goal is not to become much bigger, but…

Switzerland Giacomo Di Nepi, CEO of innovative Swiss specialty pharma outfit Polyphor, discusses his decision to join the company in 2016, his main priorities, and the potential impact of an IPO in the next two years. Having previously held senior leadership responsibilities with Takeda and Novartis, spending time as partner at…